China’s biotech sector leverages state-backed R&D and global clinical trial networks to disrupt Western pharmaceutical dominance, raising ethical and equitable access questions in oncology innovation
Original framing: “Chinese drug sector’s stature grows at major cancer conference” — South China Morning Post
China’s biotech ascent mirrors the historical trajectory of Western pharmaceutical dominance, which was built on colonial exploitation—from the forced extraction of medicinal plants (e.g., quinine from South America) to the patenting of Indigenous remedies without compensation. Similarly, China’s current model relies on state-mandated tech transfers (e.g., under ‘Made in China 2025’) and the repurposing of Western clinical trial data, replicating the same extractive logic. The ‘innovation’ narrative today ignores how China’s early biotech breakthroughs were enabled by stolen IP, such as the cloning of human insulin in the 1980s, which was developed in the U.S. before being reverse-engineered in China. This historical pattern suggests that ‘innovation’ is less about discovery and more about strategic appropriation in a new geopolitical context.
The headline’s celebration of China’s biotech ‘innovation’ obscures a geopolitical power struggle disguised as progress, where state capitalism and forced tech transfers are repackaged as ‘disruption.
’ This narrative ignores how China’s rapid ascent in oncology mirrors the historical exploitation of Indigenous knowledge and colonial extraction of pharmaceutical resources, now reenacted under a new geopolitical script. The Esmo conference’s validation of Chinese ADCs reflects a neocolonial dynamic, where Western medical authority legitimizes a model that prioritizes speed and cost over equity, safety, and cultural relevance. Marginalized voices—from clinical trial participants in rural China to patients in the Global South—are erased, while Indigenous herbal medicine systems are sidelined in favor of industrial-scale solutions. Future modelling suggests this trajectory could fragment global pharmaceutical standards, but a path forward exists through hybrid innovation hubs, regulatory alignment with ethical guardrails, and decolonizing clinical trial infrastructure. The key actors in this shift are not just pharmaceutical firms but also the regulatory bodies, patient advocacy groups, and global South governments that must collectively demand transparency, equity, and sovereignty in healthcare innovation.